Get the Stockscreener App
1.09
6.03%
-0.07
Pre-market:
1.10
0.01
+0.92%
Clearmind Medicine Inc stock is traded at $1.09, with a volume of 39,485.
It is down -6.03% in the last 24 hours and down -49.54% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$1.16
Open:
$1.16
24h Volume:
39,485
Relative Volume:
0.08
Market Cap:
$1.63M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0255
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-24.83%
1M Performance:
-49.54%
6M Performance:
-97.33%
1Y Performance:
-98.07%
1-Day Range:
$1.06
$1.16
1-Week Range:
$1.0495
$1.59
52-Week Range:
$1.0495
$58.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.09 | 1.74M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Clearmind Medicine Inc Stock (CMND) Latest News
What technical signals suggest for Clearmind Medicine Inc. stockWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
Clearmind reports positive safety results in AUD drug trial By Investing.com - Investing.com South Africa
Clearmind reports positive safety data from AUD treatment trial By Investing.com - Investing.com Nigeria
Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial - marketscreener.com
Clearmind Medicine stock falls after Phase I/IIa trial safety update By Investing.com - Investing.com South Africa
Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Nigeria
Clearmind reports positive safety data from AUD treatment trial - Investing.com
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - The Manila Times
Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com
Clearmind Medicine enters development agreement for intranasal formulation of proprietary nonhallucinogenic neuroplastogen MEAI - marketscreener.com
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - The Manila Times
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
Aug Retail: Is Clearmind Medicine Inc stock a buy or sellQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Aug Macro: Does Varonis Systems Inc have a competitive edgeJobs Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal - MSN
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - The Manila Times
Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2025 - Quiver Quantitative
Clearmind Medicine: Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk - TradingView
Will Clearmind Medicine Inc. stock deliver shareholder valueDay Trade & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine (NASDAQ:CMND) Shares Up 0.4% – What’s Next? - Defense World
Clearmind completes treatment for second cohort in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind announces completion of treatment for second cohort in CMND-100 trial - TipRanks
Clearmind Completes Treatment In 2nd Cohort Of CMND-100 Phase I/IIa Trial In Alcohol Use Disorder - Nasdaq
Clearmind completes treatment for second cohort in AUD drug trial - Investing.com
Clearmind Medicine IncTopline results from second cohort of CMND-100 expected in coming months - marketscreener.com
Clearmind Medicine Inc. Completes Treatment for Second Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News - Quiver Quantitative
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - The Manila Times
6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan
Will Clearmind Medicine Inc. outperform tech stocks2025 Trading Recap & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Aug Final Week: Does Clearmind Medicine Inc stock trade at a discount to peersJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Risk On: Is Clearmind Medicine Inc a potential multi bagger2025 Valuation Update & Safe Entry Zone Tips - baoquankhu1.vn
Why Clearmind Medicine Inc. stock remains on buy listsTrail vs Road Selection & compare fit, width, and feel - Улправда
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):